Hostname: page-component-6bf8c574d5-b4m5d Total loading time: 0 Render date: 2025-02-17T14:38:13.517Z Has data issue: false hasContentIssue false
  • English
  • Français

Corrigendum

Published online by Cambridge University Press:  02 January 2018

Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.
Type
Columns
Information
The British Journal of Psychiatry , Volume 179 , Issue 2 , August 2001 , pp. 181
Copyright
Copyright © Royal College of Psychiatrists, 2001 

Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder. Twenty-four-week placebo-controlled dose-ranging study.BJP, 179, . Figure 2 (p. 20) was incorrectly labelled as originally published, and should be:

Fig. 2. Percentage of responders at weeks 8 and 24 as assessed by a 50% reduction from baseline score in the Hamilton Rating Scale for Anxiety (HRSA) (left) or a Clinical Global Impression of Improvement (CGI-1) score of 1 or 2 (right): * P<0.05; ** P<0.01 and *** P<0.001 for venlafaxine ER v. placebo in intention-to-treat sample using the last observation carried forward method.

Figure 0

Fig. 2. Percentage of responders at weeks 8 and 24 as assessed by a 50% reduction from baseline score in the Hamilton Rating Scale for Anxiety (HRSA) (left) or a Clinical Global Impression of Improvement (CGI-1) score of 1 or 2 (right):*P<0.05; **P<0.01 and ***P<0.001 for venlafaxine ER v. placebo in intention-to-treat sample using the last observation carried forward method.

Submit a response

eLetters

No eLetters have been published for this article.